10 articles
Dror Ortho-Design disclosed in its second-quarter filing that its recurring losses and cash position of just $93,563 raise substantial doubt about its ability to continue as a going concern, and it must raise additional capital to fund operations.
Cactus Acquisition Corp. 1 Ltd. filed its annual report for 2025, disclosing a going concern warning from its auditor and reporting that it has not yet completed its planned merger with Tembo e-LV B.V., with its current operating deadline extended to November 2, 2026.
Greenwave Technology Solutions disclosed a working capital deficit of $18 million and a $522 million accumulated deficit in its latest quarterly filing, raising substantial doubt about its ability to continue as a going concern.
House of Doge dismissed its independent auditor CBIZ CPAs and hired Davidson & Company LLP, while a subsidiary issued a $1.4 million short-term note repayable in shares of CleanCore Solutions.
U.S. Gold Corp. disclosed in its annual report that its recurring losses and need for substantial project financing raise substantial doubt about its ability to continue as a going concern, while its CK Gold Project in Wyoming remains paused pending full funding.
HeartSciences Inc. reported in its annual filing that its independent auditor has expressed substantial doubt about the company's ability to continue as a going concern, citing recurring losses and the need for additional funding to support operations, regulatory clearance, and commercialization.
Alternus Clean Energy reported no revenue and a net loss for the first quarter of 2026, while its auditor reiterated substantial doubt about the company’s ability to continue as a going concern.
Regen BioPharma reached a court-approved settlement to resolve a $398,740 claim by issuing shares of its stock, and it replaced its independent auditor after that firm’s attest business was acquired.
Waste Energy Corp. disclosed in its annual report that its recurring losses and working capital deficit raise substantial doubt about its ability to continue as a going concern, while the company works toward commercial operations at its Midland, Texas facility later this year.
Cue Biopharma secured approximately $50 million through a private stock sale to fund clinical development, while its own forward-looking statement disclosures acknowledge the company still faces a going concern determination and may not have enough capital to operate beyond the next twelve months.
© 2026 Record Alpha. All rights reserved.